05:32 PM EDT, 09/11/2025 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said late Thursday it has closed its underwritten public offering of about 2.46 million shares at $7 each for gross proceeds of roughly $17.25 million.

The underwriters were granted a 30-day option to buy up to an additional 321,428 shares at the public offering price, the company said.

Net proceeds of $15.62 million are expected to be used for working capital and general corporate purposes, Actuate Therapeutics ( ACTU ) said.

Shares of the company were down over 4.9% in after-hours activity.